BiotechTube
NonExomics

NonExomics

Cambridge, United States· Est.
nonexomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

NonExomics is a private, pre-clinical stage biotech leveraging computational biology to mine the 'dark genome' for oncology applications. Its core hypothesis is that non-coding regions harbor significant, untapped potential for discovering new cancer biomarkers and drug targets. The company operates as a platform technology firm, likely seeking to advance internal programs or form discovery partnerships with larger biopharmaceutical companies. As a young, pre-revenue entity, its success hinges on validating its platform and translating computational insights into tangible therapeutic or diagnostic assets.

Oncology

Technology Platform

Proprietary computational platform for analyzing non-exomic regions of the genome to discover novel cancer biomarkers and therapeutic targets, utilizing whole-genome sequencing data and advanced bioinformatics/AI algorithms.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The vast, under-explored non-coding genome represents a major opportunity for novel target and biomarker discovery, potentially enabling more sensitive liquid biopsies and new RNA-targeted therapies.
Advances in whole-genome sequencing cost and AI for genomics create a favorable technological environment.
Growing pharma interest in precision oncology and novel modalities (ASOs, CRISPR) provides partnership and out-licensing potential.

Risk Factors

High scientific risk in functionally validating non-coding genomic hits and proving their clinical relevance as biomarkers or druggable targets.
Intense competition from academic institutions and well-funded biotech/platform companies in computational genomics.
Business model risk as a pre-revenue platform company reliant on investor funding and the need to transition from discovery to tangible assets.

Competitive Landscape

NonExomics competes with other 'dark genome' focused biotechs (e.g., Rome Therapeutics, Exo Therapeutics), large genomics platforms (Tempus, Foundation Medicine expanding beyond exome), and AI-driven drug discovery companies (Recursion, Insitro). Academic consortia like ENCODE and GTEx also provide foundational, publicly available research. Differentiation hinges on proprietary algorithms, data access, and validation speed.

More companies in United States →